olfactory receptor family 5 subfamily B member 2Genealiases: OR11-240 · OST073
Q-omics provides the consensus-scored OR5B2 profile across patient tissues and cancer cell-line models. OR5B2 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OR5B2 is differentially expressed in 2, with the highest sampling consensus in KIRP. Additionally, OR5B2 RNA expression shows 6,577 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRC, KIRP, and DLBC as cancer lineages where OR5B2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR5B2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR5B2 survival associations across molecular data types. OR5B2 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR5B2 RNA expression–survival associations across cancer types. High OR5B2 expression shows unfavorable associations in KIRC, COAD, READ, STAD and DLBC, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for OR5B2 RNA expression.
This table summarizes OR5B2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for OR5B2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR5B2 shows lower tumor expression in KIRP and higher tumor expression in PRAD. The KIRP box plot shows higher OR5B2 RNA expression in normal versus tumor tissue (log2 FC = −0.030, t-test p = .004).
This table shows molecular features associated with OR5B2 in patient tissues and cancer cell lines. In patient samples, OR5B2 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, OR5B2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Lymphoma.
